Fatty Liver Index

Pegozafermin, a fibroblast growth factor 21 analog, reduced atherogenic particles in patients with severe hypertriglyceridemia and improved liver fat and insulin resistance compared with placebo, a speaker reported.

People with a parent, sibling or child with diabetes have increased risk for developing nonalcoholic fatty liver disease, or NAFLD, regardless of their own glucose status, according to study findings.